A snapshot of lipid levels in the Republic of Ireland in 2017.
Cholesterol
Ireland
Lipid genetic disorders
Lipids
Non-fasting
Screening
Journal
Irish journal of medical science
ISSN: 1863-4362
Titre abrégé: Ir J Med Sci
Pays: Ireland
ID NLM: 7806864
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
13
11
2017
accepted:
16
04
2018
pubmed:
3
6
2018
medline:
27
3
2019
entrez:
3
6
2018
Statut:
ppublish
Résumé
Abnormalities in blood lipid levels are causally linked with cardiovascular disease and pancreatitis. Data is limited regarding lipid abnormalities in Ireland. As part of a cholesterol awareness campaign, we performed a pilot study of current lipid levels to preliminarily assess the extent and pattern of lipid abnormalities in Ireland. Non-fasting, full lipid profiles and glucose measurements were performed in 259 people (32 on lipid-lowering medication and 225 untreated) using a validated Cholestech LDX machine. Untreated participants included 95 men and 130 women, aged 51 ± 16 years. The mean ± SD, total, low-density lipoprotein (LDL), high-density lipoprotein cholesterol (HDL) and median(IQR) non-HDL cholesterol and triglyceride levels in untreated individuals were 5.0 ± 1.1, 2.8 ± 1.0, 1.5 ± 0.5 and 3.4 (2.8-4.3), 1.6 (1.0-2.3) mmol/l respectively. Glucose was 5.3 (4.8-5.8) mmol/l. Glucose > 7.8 mmol/l occurred in 10 individuals (4%). Using defined criteria for non-fasting lipid levels, 60% of participants had some form of lipid abnormality with a frequency of 47% having a total cholesterol > 5, 35% with LDL > 3.0, 26% with HDL < 1.0/1.2, 33% with triglycerides > 2.0 and 32% with non-HDL cholesterol > 3.9 mmol/l. Three individuals had untreated LDL > 5 mmol/l (i.e. a ratio of 1:75 of those tested) and eight people had HDLc < 0.7 (1:28) and four had triglyceride above 7.3 mmol/l (1:56). This pilot study reveals significant lipid abnormalities which require further larger more detailed lipid studies to assess the true burden of lipid abnormalities in Ireland. Cascade screening and genetic testing of relatives of those with severe lipid abnormalities should be considered.
Sections du résumé
BACKGROUND
BACKGROUND
Abnormalities in blood lipid levels are causally linked with cardiovascular disease and pancreatitis. Data is limited regarding lipid abnormalities in Ireland.
AIMS
OBJECTIVE
As part of a cholesterol awareness campaign, we performed a pilot study of current lipid levels to preliminarily assess the extent and pattern of lipid abnormalities in Ireland.
METHODS
METHODS
Non-fasting, full lipid profiles and glucose measurements were performed in 259 people (32 on lipid-lowering medication and 225 untreated) using a validated Cholestech LDX machine. Untreated participants included 95 men and 130 women, aged 51 ± 16 years.
RESULTS
RESULTS
The mean ± SD, total, low-density lipoprotein (LDL), high-density lipoprotein cholesterol (HDL) and median(IQR) non-HDL cholesterol and triglyceride levels in untreated individuals were 5.0 ± 1.1, 2.8 ± 1.0, 1.5 ± 0.5 and 3.4 (2.8-4.3), 1.6 (1.0-2.3) mmol/l respectively. Glucose was 5.3 (4.8-5.8) mmol/l. Glucose > 7.8 mmol/l occurred in 10 individuals (4%). Using defined criteria for non-fasting lipid levels, 60% of participants had some form of lipid abnormality with a frequency of 47% having a total cholesterol > 5, 35% with LDL > 3.0, 26% with HDL < 1.0/1.2, 33% with triglycerides > 2.0 and 32% with non-HDL cholesterol > 3.9 mmol/l. Three individuals had untreated LDL > 5 mmol/l (i.e. a ratio of 1:75 of those tested) and eight people had HDLc < 0.7 (1:28) and four had triglyceride above 7.3 mmol/l (1:56).
CONCLUSIONS
CONCLUSIONS
This pilot study reveals significant lipid abnormalities which require further larger more detailed lipid studies to assess the true burden of lipid abnormalities in Ireland. Cascade screening and genetic testing of relatives of those with severe lipid abnormalities should be considered.
Identifiants
pubmed: 29858796
doi: 10.1007/s11845-018-1820-3
pii: 10.1007/s11845-018-1820-3
doi:
Substances chimiques
Blood Glucose
0
Lipids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
241-247Références
Curr Opin Lipidol. 2006 Aug;17(4):412-7
pubmed: 16832165
Ir J Med Sci. 2006 Oct-Dec;175(4):30-5
pubmed: 17312826
Lancet. 2008 Jul 19;372(9634):224-33
pubmed: 18640459
JAMA. 2008 Nov 12;300(18):2142-52
pubmed: 19001625
N Engl J Med. 2011 Jan 13;364(2):127-35
pubmed: 21226578
Lancet. 2011 Feb 12;377(9765):578-86
pubmed: 21295847
Circ Cardiovasc Qual Outcomes. 2011 May;4(3):337-45
pubmed: 21487090
Eur Heart J. 2011 Jun;32(11):1345-61
pubmed: 21531743
Biochim Biophys Acta. 2012 May;1821(5):867-75
pubmed: 22015388
Lancet. 2012 Aug 11;380(9841):572-80
pubmed: 22607825
Gastroenterol Clin North Am. 1990 Dec;19(4):783-91
pubmed: 2269517
J Clin Endocrinol Metab. 2012 Sep;97(9):2969-89
pubmed: 22962670
JAMA. 2012 Oct 17;308(15):1545-54
pubmed: 23073951
J Am Coll Cardiol. 2013 Jan 29;61(4):427-436
pubmed: 23265341
Int J Cardiol. 2013 Oct 3;168(3):2462-7
pubmed: 23541608
Ir J Med Sci. 2013 Dec;182(4):673-8
pubmed: 23616070
Eur Heart J. 2013 Dec;34(45):3478-90a
pubmed: 23956253
N Engl J Med. 2014 Dec 18;371(25):2383-93
pubmed: 25404125
BMJ Open. 2015 Jul 13;5(7):e008017
pubmed: 26169806
Diabetes Res Clin Pract. 2015 Dec;110(3):241-9
pubmed: 26520567
J Am Coll Cardiol. 2016 Jun 7;67(22):2578-89
pubmed: 27050191
Clin Chem. 2016 Jul;62(7):930-46
pubmed: 27235445
Eur J Prev Cardiol. 2016 Dec;23(18):2007-2018
pubmed: 27638542
Ir J Med Sci. 2017 Nov;186(4):1009-1017
pubmed: 28283862
Eur Heart J. 2017 Aug 21;38(32):2459-2472
pubmed: 28444290
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Eur Heart J. 1995 Jun;16(6):752-60
pubmed: 7588918
Atherosclerosis. 1995 Nov;118(1):105-10
pubmed: 8579620
J Cardiovasc Risk. 1996 Apr;3(2):213-9
pubmed: 8836866